RecruitingNot ApplicableNCT07169825
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
Sponsor
M.D. Anderson Cancer Center
Enrollment
25 participants
Start Date
Mar 30, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Eligibility
Sex: MALE
Inclusion Criteria3
- Eligibility Criteria
- Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L.
- Participants who agree to be imaged multiple times as defined in the study protocol.
Exclusion Criteria3
- Pluvicto therapy patients without renal or marrow function complications
- Participants who do not wish to be imaged multiple times as per the study protocol.
- Women and children since this is treatment for prostate cancer.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLu-177
Given by IV
OTHERSPECT
SPECT/CT
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07169825